Author:
Wyles David,Dvory-Sobol Hadas,Svarovskaia Evguenia S.,Doehle Brian P.,Martin Ross,Afdhal Nezam H.,Kowdley Kris V.,Lawitz Eric,Brainard Diana M.,Miller Michael D.,Mo Hongmei,Gane Edward J.
Reference40 articles.
1. New hepatitis C therapies: the toolbox, strategies, and challenges;Pawlotsky;Gastroenterology,2014
2. Dvory-Sobol H, Han B, Ouyang W, Ku KS, Xu S, Worth A, et al. Susceptibility of HCV genotype 1, 2, 3 and 4 baseline clinical isolates to sofosbuvir. In: 21st International Symposium on Hepatitis C Virus and Related Viruses, Banff, Alberta, Canada, 2014.
3. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C;Lawitz;J Hepatol,2012
4. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885;Wong;Antimicrob Agents Chemother,2013
5. Cheng G, Peng B, Corsa A, Yu M, Nash M, Lee YJ, et al. Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885. In: 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, 2012.
Cited by
84 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献